When drug companies want to launch a new product, it can be a painful process. Often, they don’t know the size of the market, the share of competitive products, or how to optimize their sales force. Plus, per HIPAA law, they can only work with de-identified patient data.
MSA’s RxDx service provides exceptional pain relief by identifying top sales prospects, providing an understanding of the drug’s market position and its competitors, prioritizing sales territories, and offering access to de-identified patient data.
MSA’s patented De-Identification engine, coupled with our RxDx service delivers an unstoppable force. Pharmaceutical manufacturers, BioPharma companies, diagnostic kit producers, medical device manufacturers, and consultants should take advantage of this prodigious service.
Based on artificial intelligence-enhanced software developed over two decades, MSA is the market leader in integrating HIPAA compliant laboratory, claims, prescription and electronic medical record data at the patient level. Granular patient-level data can then be used to describe and analyze the patient journey over time from disease onset and diagnosis to treatment and outcome.
MSA’s 50+ years of data analytics experience has helped hundreds of the largest companies in the world increase their bottom line! Shouldn’t we be helping yours too?